BCL2L1 and neutropenia: Although the BCL-2 inhibitors have a number of side-effects, A1331852 and A1155463 are relatively selective BCL-XL inhibitors [14] and appear less likely to cause neutropenia than N, making them potentially better candidates for eventual translation into clinical applications.